NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE228901 Query DataSets for GSE228901
Status Public on Apr 05, 2023
Title Protectin DX as a therapeutic strategy against frailty in mice
Organism Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary Frailty in aging is driven by the dysregulation of multiple biological pathways. Protectin DX (PDX) is a docosahexaenoic acid (DHA)-derived molecule that alleviates many chronic inflammatory disorders, but its potential effects on frailty remain unknown. Our goal is to identify age-related impairments in metabolic systems and to evaluate the therapeutic potential of PDX on frailty, physical performance, and health parameters. A set of 22-month-old C57BL/6 male and female mice were assigned to vehicle (Old) or PDX daily gavage treatment for 8 weeks, whereas 6-monthold (Adult) mice received only vehicle. Forelimb and hindlimb strength, endurance, voluntary wheel activity and walking speed determined physical performance and were combined with a frailty index score and body weight loss to determine frailty status. Our data shows that old vehicle-treated mice from both sexes had body weight loss paralleling visceromegaly, and old females also had impaired insulin clearance as compared to the Adult group. Aging was associated with physical performance decline together with higher odds of frailty development. There was also age-driven mesangial expansion and glomerular hypertrophy as well as bone mineral density loss. All of the in vivo and in vitro impairments observed with aging co-occurred with upregulation of inflammatory pathways and Myc signaling as well as downregulation of genes related to adipogenesis and oxidative phosphorylation in liver. PDX attenuated the age-driven physical performance (strength, exhaustion, walking speed) decline, promoted robustness, prevented bone losses and partially reversed changes in hepatic expression of Myc targets and metabolic genes. In conclusion, our data provides evidence of the beneficial therapeutic effect of PDX against features of frailty in mice. Further studies are warranted to investigate the mechanisms of action and the potential for human translation.
 
Overall design A set of 22-month-old C57BL/6 male and female mice were assigned to vehicle (Old) or PDX daily gavage treatment for 8 weeks, whereas 6-month-old (Adult) mice received only vehicle. RNA was extracted from the liver of 15 female mice, five from each experimental group, and sequenced in order to assess the transcriptional consequences of aging and PDX treatment.
 
Contributor(s) Perazza L, Thompson L
Citation(s) 37059838
Submission date Apr 04, 2023
Last update date Apr 17, 2023
Contact name Boston University Microarray and Sequencing Resource
E-mail(s) msrdata@bu.edu
Organization name Boston University
Department Microarray and Sequencing Resource
Street address 72 East Concord Street, E631
City Boston
State/province MA
ZIP/Postal code 02118
Country USA
 
Platforms (1)
GPL30172 NextSeq 2000 (Mus musculus)
Samples (15)
GSM7142408 A1
GSM7142409 A2
GSM7142410 A3
Relations
BioProject PRJNA952121

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE228901_counts.txt.gz 683.9 Kb (ftp)(http) TXT
GSE228901_varianceStabilizingTransformation.txt.gz 2.3 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap